The Conversation (0)
NuLife Sciences announced it is initiating the second round of pre-clinical surgeries to refine the NuLife Technique through their subsidiary.
NuLife Sciences (OTCQB:NULF) announced it is initiating the second round of pre-clinical surgeries to refine the NuLife Technique through their subsidiary.
As quoted in the press release:
The series of surgeries build upon each other, and are part of the pre-clinical trial of the NuLife Technique, which commenced on August 8th at Florida International University, to evaluate the NuLife process and prove that the NuLife Technique is viable and effective.
This surgery, which is being conducted by Doctors Juan Arenas and Tjasa Hranjec, will serve to confirm results seen in the first surgery, as well as an opportunity to fine tune the NuLife Technique. Juan Arenas, MD, FACS, MBA, is a board-certified transplant surgeon, Director of the Solid Organ Transplant Institute, and the Chair of Solid Organ Transplant at Memorial Regional Hospital in Hollywood, Florida. Prior to this role, he served as the Chief of the Division of Surgical Transplantation at the University of Texas (UT) Southwestern Medical Center for the past 10 years. Tjasa Hranjec, MD, MS-CR is a Board certified trauma/critical care and transplant surgeon, the director of the Transplant Intensive Care Unit at the Memorial Regional Hospital in Hollywood.
Click here to read the full press release.
Source: www.marketwired.com